

Long-acting Injectable Second Generation Antipsychotics for Schizophrenia

	Risperidone LAI	Olanzapine LAI	Paliperidone LAI	Aripiprazole LAI
Year approved	2003	2009	2009	2013
Other indications?	Bipolar disorder	No	Schizoaffective disorder	No
Injection sites	Deltoid or gluteal	Gluteal	Deltoid or gluteal	Gluteal (approval for deltoid pending)
Needle gauge	20G or 21G	19G	22G or 23G	21G
Injection volume	~2 mL	1.0 to 2.7 mL	0.25 to 1.5 mL	2 mL (400 mg)
Injection frequency	Every 2 weeks	Every 2 or 4 weeks	Every 4 weeks	Every 4 weeks
Starting dose	25 mg	Varies from 210 mg q2wk or 405 mg q4wk to 300 mg q2wk	234 mg Day 1 + 156 mg Day 8 in deltoid	400 mg
Maintenance dose	25 mg (max 50 mg)	Varies from 150 mg q2wk or 300 mg q4wk to 300 mg q2wk	117 mg (range 39 to 234 mg)	300 or 400 mg (adjust for CYP2D6 or CYP3A4 issues)
Oral supplementation?	Yes	No	No	Yes
Reconstitution needed?	Yes	Yes	No	Yes (however, dual-chamber syringe now available)
Refrigeration needed?	Yes	No	No	No
Requires observation?	No	3 hours	No	No